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Background: Stroke causes lasting disability and the burden of stroke is expected to increase substantially during
the next decades. Optimal rehabilitation is therefore mandatory. Early supported discharge (ESD) has previously
shown beneficial, but all major studies were carried out more than ten years ago. We wanted to implement and
study the results of ESD in our community today with comparisons between ESD and treatment as usual, as well as
between two different ESD models.
Methods: Patients with acute stroke were included during a three year period (2008–11) in a randomised
controlled study comparing two different ESD models to treatment as usual. The two ESD models differed by the
location of treatment: either in a day unit or in the patients’ homes. Patients in the ESD groups were followed by a
multi-disciplinary ambulatory team in the stroke unit and discharged home as early as possible. The ESD models
also comprised treatment by a multi-disciplinary community health team for up to five weeks and follow-up
controls after 3 and 6 months. Primary outcome was modified Rankin Scale (mRS) at six months.
Results: Three-hundred-and-six patients were included. mRS scores and change scores were non-significantly better
in the two ESD groups at 3 and 6 months. Within-group improvement from baseline to 3 months was significant in
the ESD 1 (p = 0.042) and ESD 2 (p = 0.001) groups, but not in the controls. More patients in the pooled ESD groups
were independent at 3 (p = 0.086) and 6 months (p = 0.122) compared to controls and there also was a significant
difference in 3 month change score between them (p = 0.049). There were no differences between the two ESD
groups. Length of stay in the stroke unit was 11 days in all groups.
Conclusions: Patients in the ESD groups tended to be more independent than controls at 3 and 6 months, but no
clear statistically significant differences were found. The added effect of supported discharge and improved follow-up
seems to be rather modest. The improved stroke treatment of today may necessitate larger patient samples to
demonstrate additional benefit of ESD.
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Stroke is the most common cause of lasting disability in
older age, leading to both personal and familial burdens
as well as high societal costs [1,2]. The increasing inci-
dence of stroke with higher age and decreasing stroke
mortality [3], combined with an increasing number of
people in the higher age groups [4], may eventually lead
to substantially more persons suffering a stroke or having
residual symptoms from previous stroke. Optimal re-
habilitation is therefore important both for the individ-
ual stroke patient and regarding societal costs caused by
stroke.
Early supported discharge (ESD) is a rehabilitation
concept emphasising early discharge from institution to
home for patients after stroke, followed by rehabilitation
while home-dwelling, and often supervised by a specia-
lised multi-disciplinary team [5]. This has been studied
in several randomised controlled trials previously and
the results have been analysed in an updated Cochrane
report from 2012 [5]. This meta-analysis suggested a
beneficial effect of ESD for a selected group of stroke
patients, but at the same time pointed towards the need
for future studies in order to clarify which elements of
ESD in the primary health care were important, and for
more precise clarification of cost-benefit for different
patient groups. The results from eleven trials where re-
habilitation was offered either centre-based or home-
based were reviewed in a recent meta-analysis, and the
authors found a significant effect in favour of home-based
rehabilitation at 6 weeks and 3–6 months [6]. An inter-
national consensus document was recently published with
statements regarding team composition, model of team
work, intervention, and success [7].
The present ESD Stroke Bergen study was established
in order to compare the rehabilitation results after ESD
to rehabilitation as usual and to investigate the effect of
community treatment given in two different settings;
either in a day unit (ESD 1) or in the patients’ homes
(ESD 2). We therefore designed a randomised controlled
trial with two different ESD arms and one control arm,
and with two null hypotheses: (1) ESD does not improve
functional outcome evaluated by mRS; and (2) day unit
and home rehabilitation are equally effective.
Methods
Study design
The ESD Stroke Bergen study is an open randomised
controlled trial with three study arms, two for ESD and
one control arm. The study was conducted in collabor-
ation between the Department of Physical Medicine and
Rehabilitation (DPMR) and the Department of Neurology
at Haukeland University Hospital, the University of
Bergen (Department of Global Public Health and Primary
Care; Physiotherapy and Lifestyle Epidemiology ResearchGroups) and the Municipality of Bergen, Norway. The
full protocol for the study has been published previously
and should be consulted for additional details [8]. The
study was approved by the Western Norway Regional
Committee for Medical Research Ethics and registered in
ClinicalTrials.gov with registration number NCT00771771.
Patient inclusion and randomisation
All patients admitted to the stroke unit at the Department
of Neurology, Haukeland University Hospital with sus-
pected stroke were screened for inclusion. Inclusion cri-
teria were living at home in the Municipality of Bergen
prior to having a stroke, stroke within the previous seven
days, being admitted to the stroke unit within the previous
five days, and a National Institutes of Health Stroke Scale
(NIHSS) score of 2–26. The scale used in this study was a
13 items Norwegian version (range 0–34) [9]. Patients
with NIHSS score <2 were included if modified Rankin
Scale (mRS) [10] score was ≥2. The patients had to be
awake and able to agree to participation in the study by
signing an informed consent, either themselves or by their
relatives. There were no age limits. Exclusion criteria were
serious psychiatric disorders, alcohol or substance abuse,
other serious conditions of importance to the cerebral
disorder or subsequent rehabilitation process, or poor
knowledge of the Norwegian language.
Patients found eligible by a stroke physician were in-
formed by a designated nurse and asked to participate.
Participants were randomised according to a computer-
generated block randomisation list (six patients in each
block; two for each study arm) and consecutively assigned
to their groups in the same order as they were included
into the study. The randomisation list was kept by a study
coordinator and was not known to any persons in the
stroke unit. The inclusion period lasted from 8 December
2008 to 20 December 2011, and 306 patients fulfilling the
pre-specified criteria were included.
Description of study arms
Patients in two of the three study arms were treated ac-
cording to the ESD concept. They were followed by a
designated multi-disciplinary ambulatory team consist-
ing of a nurse, a physiotherapist and an occupational
therapist from soon after admission to the stroke unit
until shortly after discharge to home. This team origi-
nated from DPMR and served as a coordinating link be-
tween the patient, relatives, hospital personnel and the
personnel in the primary health care. The team was par-
ticularly important in the discharge process and coop-
erated closely with the municipal health care in the
planning and implementation of further treatment after
discharge.
The two ESD arms differed by the location of treatment:
patients in the ESD 1 group received their treatment in a
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in their homes with home-visits from the community
health team. Patients in the third study arm constituted
a control group and were treated as usual without any
intervention from the study, except appointments for test-
ing at DPMR at 3 and 6 months. The treatment “as usual”
mainly comprised institutional stay if necessary and/or
physiotherapy as needed in the municipality (0–2 hours
per week). Patients in all three study arms received lan-
guage therapy as needed, regardless of allocated arm.
The patients in the two ESD arms were discharged to
their homes as soon as possible. Patients in need of a
longer in-patient treatment period than offered by the
stroke unit were discharged to a municipal institution or
DPMR for a period before going home. All patients in
the ESD arms were offered rehabilitative treatment by a
multi-disciplinary community health team, consisting of
a nurse, a physiotherapist and an occupational therapist.
The scheduled treatment period was five weeks and
maximally four hours per day five days a week, but many
patients did not comply with this. Reasons included
tiredness, low capacity and lack of motivation, as well as
many patients being only minimally neurologically af-
fected and therefore not needing this therapy.
During the treatment period one or more persons from
the community health team were present three days a
week, and the last two the days of the week the patients
trained by themselves after instructions from the team.
Part of our study population was also studied by Gjelsvik
et al. regarding physical tests and particularly balance, and
in this subgroup mean total treatment time for the three
days per week supervised by the community health team
was 22 hours for ESD 1 and 16.6 hours for ESD 2 pa-
tients [11]. After the five week period ESD patients
were strongly encouraged to continue training and social
activities. They were also offered out-patient 3- and
6-months follow-ups at DPMR with a physician together
with a member of the DPMR multi-disciplinary ambula-
tory team.
Study outcomes and test procedures
The primary study outcome was mRS at 6 months. Sec-
ondary outcomes included mRS at 3 months, as well as
NIHSS, Barthel ADL Index (BI) [12] and patient satisfac-
tion (five-point Likert scale with 1 best) at 3 and 6 months.
Baseline tests were done before study arm allocation and
the individual patient’s group was therefore not known to
the patients or the baseline testers. Also at 3 and 6 months
the testers were blinded for study arm and the patients
were instructed not to reveal this information.
Background and clinical information relevant to the
study were prospectively registered in a database (The
Bergen NORSTROKE Registry) [13]. NIHSS was assessed
immediately after admission and repeated regularly duringthe first week. The last NIHSS score recorded during the
acute phase was used for the baseline analyses. mRS and
BI were assessed on day 7, or earlier if the patient left the
stroke unit sooner. Participants were re-tested at 3 and
6 months after inclusion at the DPMR out-patient clinic,
and for the ESD 1 and 2 groups coupled to the corre-
sponding follow-up. Control group patients were not
followed-up by the study physician and advised to contact
their general practitioner if they had medical questions of
any kind. For various reasons some patients did not want
to travel to the DPMR out-patient clinic for testing, and in
these cases NIHSS, mRS, BI and patient satisfaction were
scored by the testers coming home to the patients if
permitted.
To look for possible differences between the study arms,
information on in-patient days in hospital or municipal
institutions during the first six months after inclusion
was collected for all participants.
Statistical methods and sample size
At study start at least 400 included patients were antici-
pated, but that had been revised to 350 when the study’s
protocol was published [8]. This sample size of approxi-
mately 350 included patients was divided into two inter-
vention arms and a control arm, each of 117 patients.
Based on a previous relevant study of acute stroke pa-
tients [14] the expected proportions of patients with
mRS ≤2 at 6 months were 65% for the ESD groups and
51.9% for the control group. This provided a power of
73% (one-sided analysis) to demonstrate a statistically
significant difference between the groups.
Demographics were analysed by analysis of variance
(ANOVA) (age) and χ2-test (gender). Outcome differences
between the groups at 3 and 6 months and within-group
differences were analysed by nonparametric ANOVA
using the Kruskal-Wallis test, and by χ2-test for dichoto-
mised outcomes. Discharge destination and days in institu-
tion were analysed by χ2-test and Kruskal-Wallis test. All
analyses were done as intention-to-treat and no imputation
of missing data was made. The statistical programmes
package Stata/SE 13.1 for Windows (StataCorp LP, Texas
77845, USA) was used for all data analysis.
Results
1749 patients were screened for participation and 306
were finally included (Figure 1) reducing the power de-
scribed above to 68%. The main reasons for exclusion
were not living in Bergen (approximately 50%) or not
having suffered a confirmed stroke (approximately 25%),
whereas only 13 eligible patients declined to participate.
Seventy-three and 82% of patients in ESD groups 1 and
2, respectively, received the allocated treatment. The pa-
tients’ main reasons for not receiving the treatment were
being admitted to long-term municipal institution or
Figure 1 CONSORT flow-diagram showing patient flow from initial assessment for inclusion to six months testing in the Early supported
discharge after stroke in Bergen study.
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the allocated treatment. The drop-out rates at retest
after 3/6 months were 20%/21% in the ESD 1 group
and 14%/21% in ESD 2 group, versus 28%/33% in the
control group (Figure 1).
The participants were 55.2% men (mean age 69.6 years)
and 44.8% women (mean age 75.6 years). Age and gen-
der were not significantly different between the three
study groups (Table 1) and neither were baseline scores
for mRS, BI and NIHSS (Table 2).
The groups did not differ significantly at any point in
time for mean values of the primary outcome mRS, norfor BI and NIHSS scores as well as all change scores
(Table 2). However, the two intervention groups generally
showed somewhat better scores than the control group.
Within-group analyses from baseline to 3/6 months
showed significant improvement for the ESD 1 (p = 0.042)
and ESD 2 groups (p = 0.001) from baseline to 3 months
and a trend for improvement from baseline to 6 months,
while there was no significant within-group difference for
the control group.
Separate analyses for men and women demonstrated
a significantly better mRS mean score in men than in
women in all groups together at 3 (p = 0.006) and
Table 1 Baseline characteristics of 306 ESD Stroke Bergen study patients
All ESD 1 group ESD 2 group Control group
Variables N = 306 n = 103 n = 104 n = 99 p-value*
Age; mean (range)
All 72.24 (27–98) 70.61 (29–91) 72.00 (27–92) 74.19 (32–98) 0.152
Male 69.55 (27–92) 69.27 (29–91) 69.41 (27–92) 70.02 (32–92) 0.947
Female 75.56 (38–98) 72.21 (38–90) 75.67 (44–92) 78.81 (44–98) 0.055
Gender; n (%)
Male 169 (55.2) 56 (54.4) 61 (58.7) 52 (52.5) 0.665
Female 137 (44.8) 47 (45.6) 43 (41.3) 47 (47.5)
Abbreviation: ESD Early Supported Discharge.
*Age analysed by ANOVA; gender analysed by χ2-test.
Table 2 Descriptive statistics of modified Rankin Scale (mRS), Barthel Index (BI) and National Institutes of Health
Stroke Scale (NIHSS)* at baseline, 3 and 6 months follow-ups and of patient satisfaction at 3 and 6 months in 306 ESD
Stroke Bergen study patients
Variables All groups ESD 1 group ESD 2 group Control group p-value†
mRS; mean (SD) (n)
Baseline; all 2.59 (1.22) (306) 2.52 (1.29) (103) 2.59 (1.15) (104) 2.66 (1.23) (99) 0.711
Males 2.53 (1.22) (169) 2.52 (1.24) (56) 2.51 (1.16) (61) 2.56 (1.27) (52) 0.959
Females 2.66 (1.23) (137) 2.53 (1.36) (47) 2.70 (1.12) (43) 2.77 (1.18) (47) 0.651
3 months; all 2.45 (1.41) (242) 2.45 (1.46) (82) 2.30 (1.37) (89) 2.62 (1.40) (71) 0.316
Males #2.25 (1.34) (134) 2.32 (1.44) (44) 2.08 (1.16) (51) 2.38 (1.44) (39) 0.612
Females 2.69 (1.46) (108) 2.61 (1.48) (38) 2.61 (1.57) (38) 2.91 (1.30) (32) 0.530
6 months; all 2.52 (1.50) (229) 2.40 (1.53) (81) 2.46 (1.45) (82) 2.73 (1.52) (66) 0.410
Males §2.26 (1.42) (122) 2.17 (1.58) (42) ||2.09 (1.18) (45) 2.60 (1.50) (35) 0.248
Females 2.80 (1.54) (107) 2.64 (1.46) (39) 2.92 (1.62) (37) 2.87 (1.57) (31) 0.796
Change scores 0–3 months −0.22 (1.08) (242) −0.26 (0.93) (82) −0.36 (1.21) (89) 0.00 (1.07) (71) 0.063
Change scores 0–6 months −0.15 (1.21) (229) −0.23 (1.08) (81) −0.36 (1.21) (89) 0.00 (1.19) (66) 0.532
Barthel Index; median (IQR) (n)
Baseline 95 (40) (304) 100 (50) (102) 92.5 (35) (104) 95 (45) (98) 0.742
3 months 100 (15) (231) 100 (15) (78) 97.5 (10) (86) 100 (20) (67) 0.976
6 months 100 (15) (213) 100 (15) (76) 100 (10) (77) 100 (15) (60) 0.977
Change scores 0–3 months 0 (20) (229) 0 (20) (77) 0 (20) (86) 0 (15) (66) 0.642
Change scores 0–6 months 0 (20) (211) 0 (20) (75) 0 (20) (77) 0 (20) (59) 0.912
NIHSS; median (IQR) (n)
Baseline 3 (4) (304) 2 (4) (103) 3 (3) (104) 2 (4) (97) 0.593
3 months 2 (3) (226) 2 (3) (76) 2 (3.5) (84) 2 (3) (66) 0.925
6 months 2 (3) (205) 1 (3) (73) 1.5 (3.5) (76) 2 (3.5) (56) 0.718
Change scores 0–3 months −1 (3) (224) −1 (3) (76) −1 (3) (84) 0 (3) (64) 0.370
Change scores 0–6 months −1 (3) (203) −1 (3) (73) −1 (2) (76) −1 (3) (54) 0.615
Patient satisfaction; mean (SD) (n)
3 months 1.50 (0.99) (187) 1.32 (0.78) (62) 1.49 (0.91) (70) 1.71 (1.23) (55) 0.115
6 months 1.59 (1.08) (197) 1.62 (1.22) (73) 1.51 (0.98) (71) 1.68 (1.01) (53) 0.355
Abbreviations: ESD Early Supported Dischargem, SD Standard Deviation, IQR Interquartile Range.
*mRS range from 0 (best) to 6; BI range from 0 to 100 (best); NIHSS range from 0 (best) to 34; patient satisfaction range from 1 (best) to 5.
†All analyses: Kruskal-Wallis test; #Males better than females, p = 0.006; §Males better than females, p = 0.004; ||Males better than females, p = 0.011.
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ately at 6 months (p = 0.011). Patient satisfaction was
rated better in ESD groups 1 and 2 at 3 months (1.32
and 1.49) compared to the control group (1.71), though
not significantly (p = 0.115).
mRS and BI scores dichotomised to independency
(mRS ≤ 2; BI ≥ 95) or dependency (mRS > 2; BI < 95)
demonstrated non-significantly better results for mRS in
the intervention groups pooled together vs. the control
group (p = 0.086 at 3 months; p = 0.122 at 6 months)
(Table 3). Mean mRS scores were not significantly different
between the pooled intervention groups and the control
group at 3 (p = 0.204) and 6 months (p = 0.188). Change
score for mRS at 3 months was significantly better in the
pooled ESD groups than in the control group (p = 0.049),
but with no difference at 6 months (p = 0.319) (Table 3).
Subgroup analysis according to discharge destination
from the stroke unit (directly home [n = 171]; to munici-
pal institution [n = 78]; to DPMR [n = 47]; others/died
[n = 10, results not shown]) showed significantly poorer
mRS at 3 and 6 months for patients in the control group
discharged to DPMR (mean mRS = 3.25/3.25) compared
to the ESD 1 group (mean mRS = 2.76/2.50) and ESD 2
group (mean mRS = 2.33/2.21) (p = 0.041/0.037). Change
scores were, however, not significantly different between
the groups for 0–3 and 0–6 months. There were no dif-
ferences in mRS or mRS change scores between theTable 3 Percentage of patients independent (BI ≥ 95 or
mRS ≤ 2) and dependent (BI < 95 or mRS > 2) at baseline
and after 3 and 6 months in the ESD arms combined and
in the control arm; mRS and mRS change scores at 3 and
6 months in 306 ESD Stroke Bergen study patients
Time ESD arms (1 + 2) Control arm p-value*
Baseline
BI≥ 95; n/N (%) 108/206 (52.4) 51/98 (52.0) 0.950
mRS≤ 2; n/N (%) 109/207 (52.7) 49/99 (49.5) 0.605
3 months
BI≥ 95; n/N (%) 113/164 (68.9) 42/67 (62.7) 0.362
mRS≤ 2; n/N (%) 93/171 (54.4) 30/71 (42.3) 0.086
mRS; mean (SD) 2.37 (1.41) 2.62 (1.40) 0.204
mRS change score
0–3 months; mean (SD)
−0.31 (1.08) 0 (1.07) 0.049
6 months
BI≥ 95; n/N (%) 111/153 (72.5) 40/60 (66.7) 0.395
mRS≤ 2; n/N (%) 90/163 (55.2) 29/66 (43.9) 0.122
mRS; mean (SD) 2.43 (1.49) 2.73 (1.52) 0.188
mRS change score
0–6 months; mean (SD)
−0.21 (1.22) 0 (1.19) 0.319
Abbreviations: BI Barthel Index, mRS Modified Rankin Scale, ESD Early Supported
Discharge, SD Standard Deviation.
*Statistical tests: χ2-test (analyses of dichotomised BI and mRS) and Mann–
Whitney U-test (mRS and mRS change score), p-value <0.05 indicated in bold.groups for patients discharged home or to a municipal
institution (Table 4). In addition, the patients were di-
vided into three groups as equally sized as possible, ac-
cording to last baseline NIHSS score (0–1 [n = 88]; 2–4
[n = 130]; ≥5 [n = 86]), and mRS scores were analysed
for differences between these groups. There were some
significant differences as seen from Table 5, but they
were not clinically meaningful.
Post hoc we analysed for group differences in discharge
destination from the stroke unit, length of continuous
stay in hospital or municipal institution after the stroke
as well as total days spent in the stroke unit, DPMR and
municipal institution during the first six months after
stroke. There were no differences between the groups
(Table 6).
Discussion
The primary research aim was to investigate whether
two different ESD regimens were superior to treatment
as usual. We found, in general, small differences in
favour of the ESD groups for the outcomes mRS,
NIHSS, BI, relevant change scores and patient satisfac-
tion when examined by ANOVA, but mostly not statis-
tically significant.
We think that the main reason for these rather small
differences in rehabilitation outcome between the early
supported groups and the treatment as usual group must
be ascribed to the quite different and superior treatment
of stroke patients today, as compared to 10–15 years ago
when most previous studies were carried out. Stroke
prophylaxis is much improved, as well as acute stroke
treatment with thrombolysis being used in more than
20% of stroke patients in our region. In addition, the re-
habilitation services in general have improved during
this period, making it difficult to demonstrate further
improvement without quite large study groups.
There is also a possibility that the outcomes mRS and
BI, which are in the activities domain of the ICF, are too
blunt to detect improvements in more specific physical
functions or more qualitative outcome differences be-
tween the ESD and control treatment, e.g. regarding
quality of life. Gjelsvik et al. reported the results of phys-
ical tests in a subgroup of our patients that was dis-
charged directly from the stroke unit to their homes and
found statistically significant differences between the
groups for trunk control, self-report on walking and
ADL [11].
The power calculation for the study was based on the
results from a previous large Norwegian study carried
out in Trondheim during the period 1995–1998 [14]. In
this study the outcomes mRS and BI were dichotomised
to dependency and independency and there was a substan-
tial difference at 6 months (p = 0.017 for mRS; p = 0.056 for
BI) between patients subjected to early supported discharge
Table 4 Subgroup analyses: modified Rankin Scale (mRS) at baseline, 3 and 6 months and mRS change scores,
according to primary discharge destination in 306 ESD Stroke Bergen study patients
Discharge destination ESD 1 group ESD 2 group Control group p-value*
Home (n=171); mean (SD) (n)
Baseline 1.72 (0.88) (54) 1.97 (0.94) (60) 1.89 (0.88) (57) 0.359
3 months 1.69 (1.15) (39) 1.74 (1.16) (50) 1.93 (1.00) (44) 0.461
6 months 1.66 (1.15) (41) 2.00 (1.30) (45) 1.94 (1.15) (36) 0.514
Change score 0–3 months −0.18 (0.94) (39) −0.26 (1.23) (50) 0.07 (1.09) (44) 0.252
Change score 0–6 months −0.10 (1.04) (41) −0.05 (1.33) (45) 0.06 (1.24) (36) 0.820
Municipal Institution (n = 78); mean (SD) (n)
Baseline 3.77 (0.75) (22) 3.56 (0.87) (25) 3.65 (0.84) (31) 0.588
3 months 3.50 (1.19) (20) 3.35 (1.30) (23) 3.83 (1.29) (18) 0.521
6 months 3.60 (1.19) (20) 3.41 (1.44) (22) 3.71 (1.52) (21) 0.858
Change score 0–3 months −0.25 (0.79) (20) −0.30 (1.18) (23) 0.00 (1.19) (18) 0.509
Change score 0–6 months −0.15 (0.81) (20) −0.05 (1.46) (22) 0.05 (1.28) (21) 0.881
DPMR (n = 47); mean (SD) (n)
Baseline 3.26 (1.05) (19) 3.22 (0.73) (18) 3.70 (0.67) (10) 0.378
3 months 2.76 (0.97) (17) 2.33 (0.72) (15) 3.25 (0.71) (8) 0.041
6 months 2.50 (1.29) (14) 2.21 (0.89) (14) 3.25 (0.71) (8) 0.037
Change score 0–3 months −0.41 (1.00) (17) −0.93 (0.96) (15) −0.50 (0.53) (8) 0.258
Change score 0–6 months −0.79 (1.37) (14) −1.00 (0.88) (14) −0.50 (0.53) (8) 0.492
Abbreviations: ESD Early Supported Discharge; SD standard deviation, DPMR Department of Physical Medicine and Rehabilitation.
*All analyses: Kruskal-Wallis test, p-values <0.05 indicated in bold.
Table 5 Subgroup analyses: modified Rankin Scale (mRS) at baseline, 3 and 6 months and mRS change scores,
according to baseline NIHSS score in 306 ESD Stroke Bergen study patients
Baseline NIHSS score ESD 1 group ESD 2 group Control group p-value*
NIHSS 0–1 (n = 88); mean (SD) (n)
Baseline 1.64 (0.99) (28) 1.96 (1.02) (25) 1.83 (1.12) (35) 0.561
3 months 1.45 (0.96) (22) 2.05 (0.95) (22) 1.96 (1.15) (26) 0.109
6 months 1.32 (1.09) (22) 2.25 (0.79) (20) 2.00 (1.65) (20) 0.016
Change score 0–3 months −0.36 (0.85) (22) 0.05 (1.13) (22) 0.23 (1.34) (26) 0.187
Change score 0–6 months −0.27 (1.08) (22) 0.20 (1.11) (20) 0.20 (1.67) (20) 0.424
NIHSS 2–4 (n = 130); mean (SD) (n)
Baseline 2.35 (1.06) (48) 2.17 (0.93) (46) 2.50 (0.85) (36) 0.424
3 months 2.32 (1.34) (34) 1.74 (1.33) (38) 2.09 (0.90) (23) 0.059
6 months 2.40 (1.33) (35) 1.83 (1.42) (35) 2.25 (0.99) (24) 0.049
Change score 0–3 months −0.18 (1.00) (34) −0.47 (1.22) (38) −0.22 (0.80) (23) 0.202
Change score 0–6 months −0.11 (0.99) (35) −0.37 (1.44) (35) −0.08 (0.83) (24) 0.238
NIHSS ≥5 (n = 86); mean (SD) (n)
Baseline 3.74 (1.02) (27) 3.64 (0.74) (33) 3.88 (0.71) (26) 0.391
3 months 3.46 (1.33) (26) 3.24 (1.21) (29) 4.00 (1.21) (20) 0.114
6 months 3.38 (1.53) (24) 3.44 (1.37) (27) 3.95 (1.23) (20) 0.411
Change score 0–3 months −0.27 (0.92) (26) −0.52 (1.21) (29) 0.00 (0.97) (20) 0.168
Change score 0–6 months −0.38 (1.21) (24) −0.22 (1.40) (27) −0.05 (1.05) (20) 0.813
Abbreviations: NIHSS National Institutes of Health Stroke Scale, ESD Early Supported Discharge, SD standard deviation.
*All analyses: Kruskal-Wallis test, p-values <0.05 indicated in bold.
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Table 6 Discharge destination and days of in-patient treatment first six months after inclusion in 306 ESD Stroke
Bergen study patients
Variables All N = 306 ESD 1 group n = 103 ESD 2 group n = 104 Control group n = 99 p-value*
Discharged from stroke unit to home; n (%) 171 (55.9) 54 (52.4) 60 (57.7) 57 (57.6) 0.687
Days in institution from stroke to first
discharge home within first 6 months
after inclusion; mean (SEM)
38.4 (2.9) 37.7 (5.1) 35.6 (4.6) 42.2 (5.6) 0.881
Total days in institution from stroke
until 6 months after inclusion; mean (SEM)
45.5 (3.1) 46.0 (5.5) 42.8 (5.0) 47.7 (5.5) 0.930
Days in stroke unit 11.4 (0.4) 11.3 (0.6) 11.3 (0.7) 11.6 (0.8) 0.919
Days in DPMR 7.3 (1.2) 7.9 (2.0) 7.6 (1.9) 6.5 (2.3) 0.560
Days in municipal institution 24.0 (2.6) 23.4 (4.6) 21.5 (4.5) 27.4 (4.5) 0.111
Other 2.7 (0.4) 3.4 (0.7) 2.5 (0.5) 2.1 (0.6) 0.074
Abbreviations: ESD = Early Supported Discharge; SEM = standard error of the mean; DPMR = Department of Physical Medicine and Rehabilitation.
*Analysed by χ2-test (discharge to home) and Kruskal-Wallis test (institution days).
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models was a main objective in our study, some of our ana-
lyses were repeated with the ESD 1 and 2 groups pooled to-
gether vs. the treatment as usual group and the outcomes
mRS and BI dichotomised (Table 3). These analyses dem-
onstrated a non-significantly better result for mRS in the
two ESD groups compared to the controls (p = 0.086 at
3 months; p = 0.122 at 6 months). The corresponding mRS
change score difference at 3 months was marginally signifi-
cant (p = 0.049). There were no differences for BI.
In retrospect, such a large difference as in the Trondheim
study could not be realistically expected in our patients
now compared to their patients 15 years ago, due to the
improved acute stroke treatment and pharmacological
prophylaxis of today. Our study may therefore be consid-
ered as underpowered. We also did not reach neither the
initially intended number of at least 400 included patients
nor the revised number of 350, thereby further reducing
study power. However, we recruited almost all eligible pa-
tients during the study period and a longer recruitment
period was not realistically feasible.
We performed subgroup analyses according to the se-
verity of the initial neurological affection, based on the
suggestion that ESD models are assumed most beneficial
to stroke patients with a medium severe neurological af-
fection [5]. The patients were divided into three groups
according to last baseline NIHSS score, and mostly the
three study arms improved about equally in these three
NIHSS subgroups (Table 5). There were, however, some
statistically significant differences between mRS scores
that were clinically inconsistent and not accompanied by
significant differences in corresponding change scores,
and therefore considered to be without relevance.
We also analysed the primary outcome mRS according
to whether the patients were discharged directly to
home, to a municipal institution, to DPMR or otherwise
(other specialised institution or died in hospital). For pa-
tients discharged to DPMR before going home there wasa significant difference with the ESD 1 and ESD 2 groups
scoring better at 3 and 6 months compared to the control
group. The corresponding change scores were on the other
hand not significantly different and the clinical significance
therefore unclear. There were no differences between the
groups for the other discharge destinations.
Post-hoc we also analysed the in-patient days for pa-
tients in the three study arms, but there were no statisti-
cally significant differences in this respect as seen from
Table 6. Quite unexpectedly, there also was no difference
between the two ESD arms and the control group for
length of stay in the stroke unit (11.3, 11.3, and 11.6 days
respectively). This demonstrates that today, at least in
our region, all stroke patients are discharged from the
stroke unit as soon as possible and there is therefore not
more to gain in this respect. In fact, the determining fac-
tor for the patients’ length of stay in this study was pre-
dominantly their need for institutional stay after the
discharge from the stroke unit. Patients going directly
home spent 8.3 days in the stroke unit whereas those
needing an institutional bed after discharge stayed for
15.4 days, with only minute differences between study
arms (results not shown).
The other main research question was whether the re-
habilitation setting (day unit or home) was of importance
for the clinical outcome, but we found no differences be-
tween the groups. Hillier et al. have previously reported
on centre-based vs. home-based models in a meta-analysis
from 2010 comprising 11 trials [6]. They found home-
based treatment to be superior as measured by BI in the
early period post-discharge, while the results at 6 months
were conflicting. They concluded that the rehabilitation
should be shifted towards more home-based services and
specifically recommended that client preference should
be used to determine treatment location in individual
patients [6].
We found that men made a better recovery than women
in the two intervention groups as judged by mRS. Similar
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ported in a case–control study from 2006 that men and
women had a similar neurological recovery, whereas func-
tional recovery was better in men [15]. Wyller et al. re-
ported from Norway in 1997 that women seemed to be
functionally more impaired than men [16]. Kim et al. in
2010 reported a similar difference [17]. A possible reason
for men recovering better than women in our study may
be a higher degree of social support, since substantially
more women were living alone (results not shown).
Besides suboptimal power a major challenge in this
study was to obtain enduring compliance of included pa-
tients during the study period. They were generally old
and many found travelling to the out-patient clinic de-
manding, necessitating testing in their homes. On this
background we regard the follow-up rate in our study of
about 80-85% for the two intervention arms as satisfac-
tory. The figure of about 70% in the treatment as usual
group may be explained by these patients feeling more
weakly connected and committed to the study since they
did not receive any treatment or medical follow-up from
the project.
This study has several clinical implications. Due to the
future increase of people in high age groups and conse-
quently increased anticipated disease burden, treatment
and rehabilitation models outside specialist health care
are strongly needed. To our best knowledge this is the
first large randomised controlled trial examining ESD
after acute stroke since the pivotal studies before and
around 2000. The results indicate a slightly better im-
provement in the ESD groups compared to controls
despite a generally much improved stroke treatment.
On the other hand, the length of stay has already been
cut strongly down making it difficult to further reduce
in-patient time.
Concurrently with the planning of the present study
the Municipality of Bergen wanted to develop and
strengthen their community rehabilitation, and this en-
abled a close cooperation between our hospital and the
community during the study period. This collaboration
has led to a permanently improved rehabilitation ser-
vice in our community which will benefit patients be-
yond the stroke category. The final model for ESD
rehabilitation, and possibly rehabilitation outside of in-
stitution in general, should probably not be a question
of treatment either at home or in a day unit, but rather
a combination based on clinical judgement by the
community health team for the individual patient. This
was also suggested by Hillier et al. [6]. In the Munici-
pality of Bergen this model has now been implemented
after the study period ended. Another constraint imposed
by the RCT study was the duration of the community
health team’s treatment period, which has also been modi-
fied after study completion and is now upwards limited tothree months. There are, however, still improvements
to be made. A recent qualitative study by Taule et al.
[18] where eight stroke patients from the ESD 2 (home)
group were interviewed indicates unmet needs concerning
existential and emotional distress after stroke.Conclusions
The two ESD groups showed better functional improve-
ment than the treatment as usual group, but not statisti-
cally significant. There was no difference between the two
ESD groups. The main treatment difference between the
intervention groups and the controls turned out to be the
supported discharge with later follow-ups, since patients
were discharged equally early in all three groups.
Our interpretation: Improved prophylaxis and treatment
during the last decade has led to reduced neurological dis-
ability after stroke, in parallel with reduced in-hospital
time. The added effect of supported discharge and im-
proved follow-up seems to be rather modest and larger
patient samples are probably necessary to demonstrate a
benefit with statistical significance. In addition, the out-
come measure mRS is probably not optimal for measuring
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